Burden of leishmaniasis in Brazil and federated units, 1990-2016: Findings from Global Burden of Disease Study 2016

Bezerra, Juliana Maria Trindade; Araújo, Valdelaine Etelvina Miranda de; Barbosa, David Soeiro; Martins-Melo, Francisco Rogerlândio; Werneck, Guilherme Loureiro; Carneiro, Mariângela

doi:10.1371/journal.pntd.0006697

Cited by 74 publications

(64 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 2 Obtained by multiplying the cost of the vial (US$ 18.76) by the number of vials per day by the number of days of treatment by the recommended dosage . …”

Section: Methodsmentioning

confidence: 99%

“…1 Obtained by multiplying the cost of the vial (US$ 1.30) by the number of vials per day [2] by the number of days of treatment by the recommended dosage [20]. 2 Obtained by multiplying the cost of the vial (US$ 18.76) by the number of vials per day [3] by the number of days of treatment by the recommended dosage [7]. 3 Obtained by multiplying the average daily cost of hospitalisation (US$ 16.03) and the average duration of treatment (19.2 days).…”

Section: Sensitivity Analysismentioning

confidence: 99%

“…2 Obtained by multiplying the cost of the vial (US$ 18.76) by the number of vials per day [3] by the number of days of treatment by the recommended dosage [7]. 3 Obtained by multiplying the average daily cost of hospitalisation (US$ 16.03) and the average duration of treatment (19.2 days). 4 Obtained from the literature [10].…”

Section: Sensitivity Analysismentioning

confidence: 99%

See 2 more Smart Citations

Treatment for human visceral leishmaniasis: a cost‐effectiveness analysis for Brazil

Carvalho

Peixoto

Romero

et al. 2019

Tropical Med Int Health

View full text Add to dashboard Cite

Objective To estimate the cost‐effectiveness of strategies for the treatment of VL in Brazil. Methods Cost‐effectiveness study comparing three therapeutic options: meglumine antimoniate (MA), liposomal amphotericin B (LAMB) and a combination of LAMB plus MA (LAMB plus MA), from public health system and societal perspectives. An analytical decision‐making model was used to compare strategies for the following outcomes: early therapeutic failure avoided at 30 days, days of hospitalisation avoided and VL cure at 180 days. The efficacy and safety parameters of the drugs came from a randomised, open‐label trial and the cost data came from a cost‐of‐illness study, both carried out in Brazil. Results For all outcomes analysed, the LAMB strategy was more effective. The MA strategy was inferior to the LAMB plus MA strategy for the outcomes early therapeutic failure avoided and cure. When only LAMB and MA were compared from a societal perspective, a cost of US$ 278.56 was estimated for each additional early therapeutic failure avoided, a cost of US$ 26.88 for each additional day of hospitalisation avoided and a cost of US$ 89.88 for each additional case of cured VL, for the LAMB strategy vs. MA. Conclusion In Brazil, the LAMB strategy proved to be cost‐effective for treating VL, considering a GDP per capita as the willingness‐to‐pay threshold, for all of the outcomes analysed in comparison to MA.

show abstract

“… 2 Obtained by multiplying the cost of the vial (US$ 18.76) by the number of vials per day by the number of days of treatment by the recommended dosage . …”

Section: Methodsmentioning

confidence: 99%

Section: Sensitivity Analysismentioning

confidence: 99%

See 1 more Smart Citation

Treatment for human visceral leishmaniasis: a cost‐effectiveness analysis for Brazil

Carvalho

Peixoto

Romero

et al. 2019

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

“…The GBD data sources for Brazil have been described elsewhere [30][31][32][33][34] [30][31][32]. Additional data on the prevalence of diseases from published Brazilian populationbased studies and databases from control programs were also used in the GBD study [30][31][32].…”

Section: Gbd Overviewmentioning

confidence: 99%

Changes in malaria patterns in Brazil over 28 years (1990–2017): results from the Global Burden of Disease Study 2017

Bezerra

Barbosa

Martins-Melo

et al. 2020

Popul Health Metrics

Self Cite

View full text Add to dashboard Cite

Background This study presents the malaria burden in Brazil from 1990 to 2017 using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), by analyzing disease burden indicators in federated units of the Legal Amazon and Extra-Amazon regions, as well as describing malaria cases according to Plasmodium species occurring in the country. Methods We used estimates from the GBD 2017 to report years of life lost due to premature death (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) for malaria in Brazil, grouped by gender, age group, and Brazilian federated unit, from 1990 to 2017. Results are presented as absolute numbers and age-standardized rates (per 100,000 inhabitants) with 95% uncertainty intervals (UI). Results At the national level, the age-standardized DALYs rate due to malaria decreased by 92.0%, from 42.5 DALYs per 100,000 inhabitants (95% UI 16.6–56.9) in 1990 to 3.4 DALYs per 100,000 inhabitants (95% UI 2.7–4.7) in 2017. The YLLs were the main component of the total DALYs rate for malaria in 1990 (67.3%), and the YLDs were the main component of the metric in 2017 (61.8%). In 2017, the highest sex–age DALYs rate was found among females in the “< 1-year-old” age group, with a 6.4 DALYs per 100,000 inhabitants (95% UI 1.8–14.7) and among males in the age group of “20 to 24 years old”, with a 4.7 DALYs per 100,000 inhabitants (95% UI 3.3–9.9). Within the Brazilian Amazon region, the three federated units with the highest age-standardized DALYs rates in 2017 were Acre [28.4 (95% UI 14.2–39.1)], Roraima [28.3 (95% UI 13.5–40.2)], and Rondônia [24.7 (95% UI 11.4–34.8)]. Concerning the parasite species that caused malaria, 73.5% of the total of cases registered in the period had Plasmodium vivax as the etiological agent. Conclusions The results of the GBD 2017 show that despite the considerable reduction in the DALYs rates between 1990 and 2017, malaria remains a relevant and preventable disease, which in recent years has generated more years of life lost due to disability than deaths. The states endemic for malaria in the Amazon region require constant evaluation of preventive and control measures. The present study will contribute to the direction of current health policies aimed at reducing the burden of malaria in Brazil, as knowing the geographical and temporal distribution of the risk of death and disability of this disease can facilitate the planning, implementation, and improvement of control strategies aimed at eliminating the disease.

show abstract

“…The GBD data sources for Brazil have been described elsewhere [30,31,32,33,34]. The mortality data and the data used to generate the YLLs estimates came from the Brazilian Mortality Information System (Sistema de Informações sobre Mortalidade -SIM) and were adjusted by other national and international sources.…”

Section: Gbd Overviewmentioning

confidence: 99%

Changes in malaria patterns in Brazil over 28 years (1990-2017): results from the Global Burden of Disease Study 2017

Bezerra

Barbosa

Martins-Melo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background This study presents the malaria burden in Brazil from 1990 to 2017 using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), by analyzing disease burden indicators in federated units of the Legal Amazon and Extra Amazon regions, as well as describing malaria cases according to Plasmodium species occurring in the country. Methods We used estimates from the GBD 2017 to report years of life lost due to premature death (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) for malaria in Brazil, grouped by gender, age group, and Brazilian federated unit, from 1990 to 2017. Results are presented as absolute numbers and age-standardized rates (per 100,000 inhabitants) with 95% uncertainty intervals (UI). Results At the national level, the age-standardized DALYs rate due to malaria decreased by 92.0%, from 42.5 DALYs per 100,000 inhabitants (95% UI 16.6–56.9) in 1990 to 3.4 DALYs per 100,000 inhabitants (95% UI 2.7–4.7) in 2017. The YLLs were the main component of the total DALYs rate for malaria in 1990 (67.3%), and the YLDs were the main component of the metric in 2017 (61.8%). In 2017, the highest sex-age DALYs rate was found among females in the “<1 year old” age group, with a 6.4 DALYs per 100,000 inhabitants (95% UI 1.8–14.7) and among males in the age group of “20 to 24 years old”, with a 4.7 DALYs per 100,000 inhabitants (95% UI 3.3–9.9). Within the Brazilian Amazon region, the three federated units with the highest age-standardized DALYs rates in 2017 were Acre [28.4 (95% UI 14.2–39.1)], Roraima [28.3 (95% UI 13.5–40.2)], and Rondônia [24.7 (95% UI 11.4–34.8)]. Concerning the parasite species that caused malaria, 73.5% of the total of cases registered in the period had Plasmodium vivax as the etiological agent. Conclusions The results of the GBD 2017 show that despite the considerable reduction in the DALYs rates between 1990 and 2017, malaria remains a relevant and preventable disease, which in recent years has generated more years of life lost due to disability than deaths. The states endemic for malaria in the Amazon region require constant evaluation of preventive and control measures. The present study will contribute to the direction of current health policies aimed at reducing the burden of malaria in Brazil, as knowing the geographical and temporal distribution of the risk of death and disability of this disease can facilitate the planning, implementation and improvement of control strategies aimed at eliminating the disease.

show abstract

Burden of leishmaniasis in Brazil and federated units, 1990-2016: Findings from Global Burden of Disease Study 2016

Cited by 74 publications

References 45 publications

Treatment for human visceral leishmaniasis: a cost‐effectiveness analysis for Brazil

Treatment for human visceral leishmaniasis: a cost‐effectiveness analysis for Brazil

Changes in malaria patterns in Brazil over 28 years (1990–2017): results from the Global Burden of Disease Study 2017

Changes in malaria patterns in Brazil over 28 years (1990-2017): results from the Global Burden of Disease Study 2017

Contact Info

Product

Resources

About